Breast Cancer

Epirubicin clinical trial shows treatment improves survival rate

Published in Clinical Oncology Week, June 30th, 2003

Results from the largest trial of its kind show that a particular chemotherapy regime, which includes a drug called Epirubicin (Pharmacia & Upjohn Co.), can prevent breast cancer recurrence following surgery and reduce deaths from the disease.

The results of the British trial were announced on the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Dr. Chris Poole from the Cancer Research U.K. Clinical Trials Unit at the University of Birmingham said, "Modern chemotherapy treatments usually involve a cocktail of drugs that work together to help prevent cancer recurrence. Through clinical trials these...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2003-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry